Amgen Inc
Latest Amgen Inc News and Updates
Tezepelumab Could Help Amgen Develop Its Inflammation Franchise
According to World Health Organization (or WHO), around 235 million individuals worldwide have asthma.
Amgen’s Pipeline Could Boost Its Long-Term Growth Opportunities
EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.
How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
How Did Novartis Perform in 1H17?
In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis.
Eylea Leads the Retinal Diseases Sector
In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.
Sparsentan May Be Solid Near-Term Growth Driver for Ligand
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta
Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
Erwinaze Sales May Remain Flat in 2017
Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.
Celgene’s Revlimid Witnessed High Growth in 2Q17
In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.
Upadacitinib: Opportunity for AbbVie’s Long-Term Growth?
ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz.
Pfizer Sees a Significant Opportunity in This for Revenue Growth
In 2016, Pfizer’s (PFE) biosimilar business reported revenues of ~$319 million, compared with $63 million in 2015.
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
A Look at Allergan’s Performance in 2Q17
Allergan Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: US Specialized Therapeutics, US General Medicine, and International. Stock price performance Allergan’s stock price has risen ~1.4% in 2Q17, and 15.0% year-to-date as of July 7, 2017. […]
Merck & Co.’s Animal Health Segment’s 1Q17 Revenues
The global revenues from Merck’s Animal Health business totaled $939 million during 1Q17—13% growth over 1Q16.
A Look at Pfizer’s Revenue for 1Q17
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
This Product Pipeline Brings Hope for AbbVie’s Future Growth
AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions.
AstraZeneca’s Segment-by-Segment Performance in 1Q17
AstraZeneca’s (AZN) business is separated into four segments: Respiratory, Cardiovascular and Metabolic Diseases (or CVMD), Oncology, and Other.
Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
Amgen’s Repatha Could Gain Market Share in 2017
In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.
What Could Drive Amgen’s Growth in 2017?
Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.
Novartis’s 1Q17 Earnings: Recent Developments
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio
On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).
Could Novartis’s CTL019 Capture Significant Market Share?
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Inside Sanofi’s Overall Revenue Performance in 2016
Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.
Entresto Could See Strong Uptake in European Markets in 2017
Novartis (NVS) has managed to secure reimbursement in 17 countries in Europe.
How Novartis Is Aiming to Increase Entresto Sales in 2017
In 2017, Novartis (NVS) expects its heart failure drug, Entresto, to earn revenues in excess of $500 million.
Reduced Co-pays May Boost Demand for Entresto
Compared to 43% at the end of 2015, Novartis’s (NVS) Entresto managed to attain a preferred formulary position in 66% of commercial plans in the US at the end of 2016.
Why Entresto Could Become Key Growth Driver for Novartis in 2017
Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.
Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market.
Merck’s Keytruda Saw Impressive Growth in 2016
Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.
Growth of AstraZeneca’s Oncology Segment in 2016
The revenues for AstraZeneca’s (AZN) Oncology segment rose ~20% at constant exchange rates in 2016.
Inside Novartis’s Generics Performance in 4Q16
Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.
Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.
GlaxoSmithKline’s Revenue Trend
GlaxoSmithKline reported a rise of 23% in its 3Q16 revenue. The company met Wall Street analysts’ consensus 3Q16 estimates for revenue and earnings per share.
The Competitive Landscape for Enbrel
Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015.
SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent’s Label
In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.
Dupixent: Leading Therapy for Atopic Dermatitis in the Future?
Existing treatment options for AD aren’t tolerated well by the entire patient population. Dupixent might become a preferred regimen in the future.
A Look at Teva’s Dominance in the Biosimilar Space
As one of the early entrants in biosimilars, Teva Pharmaceutical Industries (TEVA) has managed to become one of the biggest players in the biosimilar space.
Pfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion.
Pfizer’s Essential Health Business: What You Need to Know
In this series, we’ll discuss in detail how Pfizer plans to revive growth for the falling Essential Health business.
A Look at Pfizer’s Innovative Health Business
In the second quarter of 2016, Pfizer (PFE) reorganized its Innovative Pharmaceutical and Consumer Healthcare operations as the Innovative Health business segment.
Why Pfizer’s Enbrel Faces a Sales Decline
Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively.
Amgen’s Bone Health Drug Saw Strong Revenue Growth in 2Q16
Amgen’s (AMGN) bone health drugs Prolia and Xgeva earn a combined $3 billion in revenue annually.
Regeneron’s Robust Pipeline
Regeneron’s (REGN) robust pipeline consists of 13 molecules in various phases of development. Sarilumab is under review with the FDA.
Why Is AbbVie’s Valuation Multiple Rising in July?
AbbVie believes that the Market has misunderstood the growth potential of Rova-T, which is expected to earn $1.5 billion–$2 billion in peak sales even under extremely conservative assumptions.
Can Stemcentrx’s Cancer Stem Cell Technology Really Accelerate Innovation for AbbVie?
The acquisition of Stemcentrx has added CSC (cancer stem cell) technology platform to AbbVie’s (ABBV) oncology portfolio.
Venclexta: The First BCL-2 Inhibitor Cancer Therapy to Be Approved by the FDA
On April 11, 2016, Venclexta became the first BCL-2 inhibitor therapy to be approved by the FDA for chronic lymphocytic leukemia patients with 17p deletion.
